<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408445</url>
  </required_header>
  <id_info>
    <org_study_id>14-1720</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02408445</nct_id>
  </id_info>
  <brief_title>Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment</brief_title>
  <official_title>Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study in infant males with Klinefelter syndrome (47,XXY) will learn more about
      body composition (muscle and fat) and male hormones and look at the effect of testosterone
      shots on body composition. The Investigators know that older boys and men with Klinefelter
      syndrome often have more fat compared to muscle than adults without Klinefelter syndrome, but
      we do not know if this difference is present at birth or develops over time. The
      Investigators will learn if body composition and motor skills are improved with testosterone
      treatment in infants with Klinefelter syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2015</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Fat Percent Z-score</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Body fat percentage will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period. Age and sex-normed z-scores will be calculated. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Change in the z-score over time, if following a normal growth curve, is 0. Positive change in z-scores indicates a gain in body fat above growth typically expected. Negative change in z-scores indicates a gain in body fat that is less than typically expected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Luteinizing Hormone (LH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive LH will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive FSH will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Total testosterone by mass spectroscopy will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Inhibin B (INHB)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Inhibin B levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Mullerian Hormone (AMH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. AMH levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Leptin levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Raw Score on the Alberta Infant Motor Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Alberta Infant Motor Scale (AIMS). The AIMS scale measures infant motor maturation from birth until the age of independent walking. An occupational therapists assesses 58 motor behavior items in 4 position categories: prone (21 items), supine (9 items), sitting (12 items) &amp; standing(16 standing). Each item receives one point (range of raw scores 0-58), with higher scores indicating more skills acquired. For change in scores, the raw score at 3 months was subtracted from the baseline raw score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on the Movement Assessment of Infants (MAI)</measure>
    <time_frame>3 months</time_frame>
    <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Movement Assessment of Infants (MAI). The MAI evaluates four domains: muscle tone, primitive reflex, automatic reactions and volitional movement. All items are scored 1-5 and summed to generate a &quot;Total Risk Score&quot;. Lower scores indicate better function, and Total Risk Scores of 8 or more indicate high risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Motor Standard Score on the Peabody Developmental Motor Scales 2</measure>
    <time_frame>3 months</time_frame>
    <description>Motor development will be assessed by an occupational therapist using the standardized Peabody Developmental Motor Scales 2. Standard scores are normalized to age with a mean of 100 and standard deviation of 15. Change in standard score was calculated as the differences between the subject's standard score at 3 months minus the standard score at baseline. A positive change in standard scores would indicate greater growth on the measure relative to peers, while a negative number would indicate slower growth on the measure relative to peers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Length</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Stretched penile length will be measured by a physician before randomization and at the end of the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fat Free Mass</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Fat free mass (lean mass) will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Klinefelter Syndrome</condition>
  <arm_group>
    <arm_group_label>Testosterone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone cypionate (200 mg/ml) intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not receive any testosterone during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone cypionate 200mg/ml</intervention_name>
    <description>Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
    <arm_group_label>Testosterone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male infants with 47,XXY karyotype

        Exclusion Criteria:

          -  Gestational age at birth &lt;36 weeks

          -  Birth weight &lt;5%ile or &gt;95% for gestational age

          -  History of thrombosis in a first degree relative

          -  Exposure to androgen therapy outside of the study protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>108 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanlee M Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <results_first_submitted>February 21, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2020</results_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>body composition</keyword>
  <keyword>Klinefelter syndrome</keyword>
  <keyword>XXY</keyword>
  <keyword>sex chromosome variation</keyword>
  <keyword>sex chromsome aneuploidy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Klinefelter Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02408445/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02408445/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Treatment</title>
          <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Subjects will not receive any testosterone during the study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Treatment</title>
          <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Subjects will not receive any testosterone during the study period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="22"/>
                    <measurement group_id="B2" value="70" spread="23"/>
                    <measurement group_id="B3" value="72" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Fat Percent Z-score</title>
        <description>Body fat percentage will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period. Age and sex-normed z-scores will be calculated. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Change in the z-score over time, if following a normal growth curve, is 0. Positive change in z-scores indicates a gain in body fat above growth typically expected. Negative change in z-scores indicates a gain in body fat that is less than typically expected.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Fat Percent Z-score</title>
          <description>Body fat percentage will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period. Age and sex-normed z-scores will be calculated. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Change in the z-score over time, if following a normal growth curve, is 0. Positive change in z-scores indicates a gain in body fat above growth typically expected. Negative change in z-scores indicates a gain in body fat that is less than typically expected.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.65"/>
                    <measurement group_id="O2" value="0.92" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Luteinizing Hormone (LH)</title>
        <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive LH will be measured.</description>
        <time_frame>baseline only</time_frame>
        <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Luteinizing Hormone (LH)</title>
          <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive LH will be measured.</description>
          <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.1"/>
                    <measurement group_id="O2" value="2.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Follicle Stimulating Hormone (FSH)</title>
        <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive FSH will be measured.</description>
        <time_frame>baseline only</time_frame>
        <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Follicle Stimulating Hormone (FSH)</title>
          <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive FSH will be measured.</description>
          <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                    <measurement group_id="O2" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone</title>
        <description>Serum will be collected at the first study visit prior to randomization. Total testosterone by mass spectroscopy will be measured.</description>
        <time_frame>baseline only</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone</title>
          <description>Serum will be collected at the first study visit prior to randomization. Total testosterone by mass spectroscopy will be measured.</description>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" spread="100"/>
                    <measurement group_id="O2" value="166" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Inhibin B (INHB)</title>
        <description>Serum will be collected at the first study visit prior to randomization. Inhibin B levels will be measured.</description>
        <time_frame>baseline only</time_frame>
        <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Inhibin B (INHB)</title>
          <description>Serum will be collected at the first study visit prior to randomization. Inhibin B levels will be measured.</description>
          <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" spread="96"/>
                    <measurement group_id="O2" value="355" spread="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Anti-Mullerian Hormone (AMH)</title>
        <description>Serum will be collected at the first study visit prior to randomization. AMH levels will be measured.</description>
        <time_frame>baseline only</time_frame>
        <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Anti-Mullerian Hormone (AMH)</title>
          <description>Serum will be collected at the first study visit prior to randomization. AMH levels will be measured.</description>
          <population>Analysis was completed only on subjects for which sufficient blood was able to be obtained and that has been measured at this time.</population>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1377" spread="688"/>
                    <measurement group_id="O2" value="2208" spread="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leptin</title>
        <description>Serum will be collected at the first study visit prior to randomization. Leptin levels will be measured.</description>
        <time_frame>baseline only</time_frame>
        <population>Unable to be analyzed due to insufficient quantities of serum collected. Prioritized hormone assays first.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin</title>
          <description>Serum will be collected at the first study visit prior to randomization. Leptin levels will be measured.</description>
          <population>Unable to be analyzed due to insufficient quantities of serum collected. Prioritized hormone assays first.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Raw Score on the Alberta Infant Motor Scale</title>
        <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Alberta Infant Motor Scale (AIMS). The AIMS scale measures infant motor maturation from birth until the age of independent walking. An occupational therapists assesses 58 motor behavior items in 4 position categories: prone (21 items), supine (9 items), sitting (12 items) &amp; standing(16 standing). Each item receives one point (range of raw scores 0-58), with higher scores indicating more skills acquired. For change in scores, the raw score at 3 months was subtracted from the baseline raw score.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Raw Score on the Alberta Infant Motor Scale</title>
          <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Alberta Infant Motor Scale (AIMS). The AIMS scale measures infant motor maturation from birth until the age of independent walking. An occupational therapists assesses 58 motor behavior items in 4 position categories: prone (21 items), supine (9 items), sitting (12 items) &amp; standing(16 standing). Each item receives one point (range of raw scores 0-58), with higher scores indicating more skills acquired. For change in scores, the raw score at 3 months was subtracted from the baseline raw score.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="4.9"/>
                    <measurement group_id="O2" value="8.9" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on the Movement Assessment of Infants (MAI)</title>
        <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Movement Assessment of Infants (MAI). The MAI evaluates four domains: muscle tone, primitive reflex, automatic reactions and volitional movement. All items are scored 1-5 and summed to generate a &quot;Total Risk Score&quot;. Lower scores indicate better function, and Total Risk Scores of 8 or more indicate high risk.</description>
        <time_frame>3 months</time_frame>
        <population>Data for this measurement was not collected for any of the participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on the Movement Assessment of Infants (MAI)</title>
          <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Movement Assessment of Infants (MAI). The MAI evaluates four domains: muscle tone, primitive reflex, automatic reactions and volitional movement. All items are scored 1-5 and summed to generate a &quot;Total Risk Score&quot;. Lower scores indicate better function, and Total Risk Scores of 8 or more indicate high risk.</description>
          <population>Data for this measurement was not collected for any of the participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Motor Standard Score on the Peabody Developmental Motor Scales 2</title>
        <description>Motor development will be assessed by an occupational therapist using the standardized Peabody Developmental Motor Scales 2. Standard scores are normalized to age with a mean of 100 and standard deviation of 15. Change in standard score was calculated as the differences between the subject's standard score at 3 months minus the standard score at baseline. A positive change in standard scores would indicate greater growth on the measure relative to peers, while a negative number would indicate slower growth on the measure relative to peers.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Motor Standard Score on the Peabody Developmental Motor Scales 2</title>
          <description>Motor development will be assessed by an occupational therapist using the standardized Peabody Developmental Motor Scales 2. Standard scores are normalized to age with a mean of 100 and standard deviation of 15. Change in standard score was calculated as the differences between the subject's standard score at 3 months minus the standard score at baseline. A positive change in standard scores would indicate greater growth on the measure relative to peers, while a negative number would indicate slower growth on the measure relative to peers.</description>
          <units>change in standard score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="7.3"/>
                    <measurement group_id="O2" value="2.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Length</title>
        <description>Stretched penile length will be measured by a physician before randomization and at the end of the study period.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Length</title>
          <description>Stretched penile length will be measured by a physician before randomization and at the end of the study period.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.5"/>
                    <measurement group_id="O2" value="-0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fat Free Mass</title>
        <description>Fat free mass (lean mass) will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Treatment</title>
            <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not receive any testosterone during the study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Free Mass</title>
          <description>Fat free mass (lean mass) will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Adverse events were captured by parental report in the active treatment arm only. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed for the 'No Treatment' Arm/Group</desc>
      <group_list>
        <group group_id="E1">
          <title>Testosterone Treatment</title>
          <description>Testosterone cypionate (200 mg/ml) intramuscular injection
testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>acne</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="gi">Change in diet or elimination habits</sub_title>
                <description>Parent reported change in appetite, diarrhea, constipation, or other GI-symptom</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mood change</sub_title>
                <description>Parent-reported change in mood/demeanor, including irritability, level of alertness, sleepiness, etc.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erections</sub_title>
                <description>Parent report of penile erections (&gt;1 erection noted)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <description>any parent-reported pimples</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shanlee Davis</name_or_title>
      <organization>University of Colorado</organization>
      <phone>720-777-6073</phone>
      <email>shanlee.davis@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

